angiotensin IV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Furthermore, Atracium produces a toxic metabolite called laudanosine when administered and can accumulate in patients with impaired renal function. This may lead to potential seizures and epilepsy. Thus, the dosage of the atracium should be compensated for patients with decreased renal functions. Vecuronium: Most of vecuronium's adverse effects is correlated to the drug's extension of pharmacological effects past the desired time of use. Serious adverse effects include bronchospasm, anaphylaxis, apnea, and prolonged paralysis. In some instances, hypersensitivity-associated histamine release may occur, leading to allergy-like symptoms or severe anaphylaxis in rare cases. Vecuronium has a relatively favourable safety profile when compared to pancuronium or other aminosteroid non-depolarizing drugs. Pancuronium: Pancuronium produces more significant adverse effects due to the blockade of muscarinic M2 receptors in the atria. Therefore, pancuronium may increase cardiac output, mean arterial pressure, and heart rate. To add on, patients with renal failure may experience a 30-50% decrease in plasma clearance, hence an increase in neuromuscular blockade duration. The use of pancuronium with insufficient anesthetic agents leads to morbidity and psychological trauma. Acetylcholinesterase inhibitor Donepezil: Donepezil may exhibit cardiac issues such as hypertension, cardiac arrhythmia, atrioventricular block, and bradycardia due to its vagotonia properties.
Dominion Voting Systems sues Mike Lindell for $1.3 billion for defamation, claiming he spread false conspiracy theories about them after the 2020 presidential election. COVID-19 pandemic – The United States surpasses 500,000 deaths from COVID-19. In response, President Biden orders flags to fly at half-mast for five days. February 23 Golf champion Tiger Woods is seriously injured in a car crash, and undergoes surgery at Harbor–UCLA Medical Center. February 24 – COVID-19 pandemic: Johnson & Johnson's vaccine candidate receives emergency use authorization from the FDA. The single-shot vaccine is 66% effective in combating the virus and can be stored in regular, unspecialized refrigerators. February 25 COVID-19 pandemic: The number of vaccines administered in the United States exceeds 50 million. The U.S. Food and Drug Administration approves Amondys 45 for the treatment of Duchenne muscular dystrophy. This is the first FDA-approved targeted treatment for people with the exon 45 skipping mutation. February 26 Washington's felony drug possession law is struck down as unconstitutional by the Washington Supreme Court, making Washington the 2nd state (after Oregon) to remove criminal penalties for possession of illicit drugs. Representative Paul Gosar and former Representative Steve King attend The America First Political Action Conference, whose organizer is Nick Fuentes. Gosar's attendance was the subject of controversy. February 27 The House of Representatives passes the American Rescue Plan Act, President Biden's $1.9 trillion COVID-19 relief package.
A buffer buffers most effectively around its pKa value, so the pKa of the buffer should be close to the desired mobile phase pH. The buffer must be compatible with the solvent that is being used in the mobile phase, mostly with the common organic solvents mentioned above, acetonitrile, methanol, and isopropanol. If UV absorption spectroscopy is used for detection, the buffer should have low absorption at the chosen wavelength. If mass spectrometry (MS) is used for detection, the buffer must be compatible with the MS instrument. Some buffers, such as those containing phosphate salts, cannot be used with the MS detectors, as they are not volatile, and they suppress the analytes ionization, making them undetected by MS. Charged analytes can also be separated by ion interaction reverse-phase chromatography.
Sources: en.wikipedia.org
=== Schizophrenia === Risperidone is effective in treating psychogenic polydipsia and the acute exacerbations of schizophrenia. Studies evaluating the utility of risperidone by mouth for maintenance therapy have reached varying conclusions. A 2012 systematic review concluded that evidence is strong that risperidone is more effective than all first-generation antipsychotics other than haloperidol, but that evidence directly supporting its superiority to placebo for negative symptoms is equivocal. A 2011 review concluded that risperidone is more effective in relapse prevention than other first- and second-generation antipsychotics with the exception of olanzapine and clozapine. A 2016 Cochrane review suggests that risperidone reduces the overall symptoms of schizophrenia, but firm conclusions are difficult to make due to very low-quality evidence. Data and information are scarce, poorly reported, and probably biased in favour of risperidone, with about half of the included trials developed by drug companies. The article raises concerns regarding the serious side effects of risperidone, such as parkinsonism. A 2011 Cochrane review compared risperidone with other atypical antipsychotics such as olanzapine for schizophrenia, concluding it produced a somewhat higher risk of extrapyramidal side effects. Long-acting injectable formulations of antipsychotic drugs provide improved compliance with therapy and reduce relapse rates relative to oral formulations.
== Overdose == There is limited experience with overdose of suvorexant. Suvorexant has been assessed in single doses of as high as 240 mg in clinical studies. The medication dose-dependently produces somnolence. High doses of suvorexant may also cause sleep-onset paralysis in some individuals (2% incidence at doses of 40–240 mg). Treatment of suvorexant overdose is based on symptoms and is supportive. Gastric lavage may be used where appropriate whereas the value of dialysis has not been determined. Because suvorexant has high plasma protein binding, hemodialysis is not expected to enhance elimination of suvorexant.
== Disadvantages == However, there are some concerns associated with DBS biosampling. These include challenges related to sample volume, analyte recovery, the hematocrit effect, sample homogeneity, and the characteristics of the filter paper used.
=== Transportation companies === Canadian Airlines (1987–2001) (IATA airline code CP) Canadian Pacific Railway, reporting mark CP Central Pacific Railroad, a network of lines between California and Utah, US Chemins de Fer de Provence, a French public railway company Comboios de Portugal, a Portuguese state-owned train company CP Air or Canadian Pacific Air Lines (1942–1987), a Canadian airline CP Ships, a Canadian shipping company, part of TUI Group Cathay Pacific, a Hong Kong–based major airline
Sources: en.wikipedia.org
=== Meiosis === When C. brunneus was exposed to X-irradiation during the zygotene-early pachytene stages of meiosis, this treatment caused a significant increase in meiotic cell chiasma frequency. Chiasma frequency was scored during the subsequent diplotene-diakinesis stages of meiosis.
In addition to psychedelics being defined as controlled substances at the federal level, individual U.S. states, such as Alabama, may also make psychedelics controlled substances within their jurisdictions. Conversely, state-level and lower jurisdictions may alternatively legalize or decriminalize psychedelics, for instance Colorado and Oregon and individual cities like San Francisco. This can result in legal conflict and ambiguity at different levels of government, for example a given drug being illegal at the federal level but legal at the state level.
P3 peptides are thought to have a role in neuronal death and in the enhanced inflammatory response in AD and DS, as it has been demonstrated that the treatment of cells with the p3 fragment, induced by the c-Jun N-terminal kinases (JNK) phosphorylation, is involved in neuronal cells apoptosis and causes the death of SH-SY5Y and IMR‐32 human neuroblastoma cells.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.